<SEC-DOCUMENT>0001193125-13-096310.txt : 20130307
<SEC-HEADER>0001193125-13-096310.hdr.sgml : 20130307
<ACCEPTANCE-DATETIME>20130307172723
ACCESSION NUMBER:		0001193125-13-096310
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130307
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130307
DATE AS OF CHANGE:		20130307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-16731
		FILM NUMBER:		13674445

	BUSINESS ADDRESS:	
		STREET 1:		951 BROKEN SOUND PARKWAY NW
		STREET 2:		SUITE 320
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		951 BROKEN SOUND PARKWAY NW
		STREET 2:		SUITE 320
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d499155d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): March&nbsp;7, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>TherapeuticsMD, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in its Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-16731</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>87-0233535</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>951 Broken Sound Parkway NW, Suite 320 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Boca Raton, FL 33487 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Office) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s
telephone number, including area code: (561)&nbsp;961-1911 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction A.2 below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Regulation FD Disclosure. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;7, 2013, TherapeuticsMD, Inc. (the &#147;Company&#148;) issued a press release announcing that it intends to offer and sell,
subject to market and other conditions, $50,000,000 of its common stock in an underwritten public offering (the &#147;Offering&#148;). Jefferies LLC is acting as sole book-running manager for the Offering, and Noble Financial Capital Markets is
acting as co-manager for the Offering. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. A copy of the press release is attached hereto as Exhibit 99.1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information contained in this Item&nbsp;7.01 and in Exhibit 99.1 shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such a filing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except for the historical information contained herein, the matters set forth in this Item&nbsp;7.01 and in Exhibit 99.1, including
statements regarding the Company&#146;s expectations with respect to the completion, timing and size of the Offering, are forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market conditions, the satisfaction of customary
closing conditions related to the Offering, risks and uncertainties associated with the Company&#146;s business and finances in general, and other risks detailed in the Company&#146;s annual report on Form 10-K filed with the SEC on March&nbsp;27,
2012, current report on Form 8-K filed with the SEC on January&nbsp;25, 2013, and other filings with the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this report. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any
forward-looking statement to reflect events or circumstances after the date of this report. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exhibits.</I> </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release from TherapeuticsMD, Inc., dated March&nbsp;7, 2013, entitled &#147;TherapeuticsMD Announces $50,000,000 Proposed Public Offering of Common
Stock&#148;.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: March&nbsp;7, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">THERAPEUTICSMD, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Daniel A. Cartwright</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel A. Cartwright</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release from TherapeuticsMD, Inc., dated March 7, 2013, entitled &#147;TherapeuticsMD Announces $50,000,000 Proposed Public Offering of Common Stock&#148;.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d499155dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g4991551.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;FOR IMMEDIATE RELEASE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">SYMBOL: TXMD&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;7, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">TRADED: OTCQB</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THERAPEUTICSMD ANNOUNCES $50,000,000 PROPOSED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PUBLIC OFFERING OF COMMON STOCK </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>BOCA RATON, FL</B>&#151;March 7, 2013&#151;TherapeuticsMD, Inc. (OTCQB: TXMD) today announced that it intends to offer and sell, subject to market and other conditions, $50,000,000 of its common stock
in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Jefferies LLC is acting as sole book-running manager for the offering, and Noble Financial Capital Markets is acting as co-manager for the offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A shelf registration statement relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange
Commission (SEC) and is effective. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC&#146;s website located at <U>www.sec.gov</U>. Copies of the preliminary prospectus supplement
and the accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by telephone at
(877)&nbsp;547-6340, or by e-mail at <U>Prospectus_Department@Jefferies.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release shall not constitute an offer to sell or
the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale is not permitted. Any offer, if at all, will be made only by means of
a prospectus, including a prospectus supplement, forming part of the effective shelf registration statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About TherapeuticsMD
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">TherapeuticsMD, Inc. is a women&#146;s healthcare product company focused on creating and commercializing products targeted exclusively
for women. The Company currently manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins and cosmetics. The Company is currently focused on conducting the clinical trials necessary for
regulatory approval and commercialization of advanced hormone therapy pharmaceutical products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Forward-Looking Statements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Except for the historical information contained herein, the matters set forth in this press release, including statements regarding
TherapeuticsMD&#146;s expectations with respect to the completion, timing and size of its proposed offering, are forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market conditions, the satisfaction of customary closing
conditions related to the proposed offering, risks and uncertainties associated with TherapeuticsMD&#146;s business and finances in general, and other risks detailed in TherapeuticsMD&#146;s annual report on Form 10-K filed with the SEC on
March&nbsp;27, 2012, current report on Form 8-K filed with the SEC on January&nbsp;25, 2013, and other filings with the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and TherapeuticsMD undertakes no obligation to revise
or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contact: Daniel A.
Cartwright </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">TherapeuticsMD, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(561) 961-1911 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>dan.cartwright@therapeuticsmd.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"># # # </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g4991551.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4991551.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)0$7`P$1``(1`0,1`?_$`,D```$$`@,!`0``````
M``````D!!P@*``(#!08$"P$``00#`0``````````````!@$"!0<``P0($```
M!@$"!`,$!P0'!`L````!`@,$!08'$0@`(1(),4$382(4%5&!,D(C%@IQD1<8
MH5)B,U,DM['!T7=RHD-CM#4F-QD:.A$``0$&`P4%!`<$!P4)`````0(`$0,$
M!08A,1)!46$3!W&!H2(RD;'!%/#1X4(C%0CQ8K(64G*",W,D-U-CDV0E-$1T
M-74V%R<8_]H`#`,!``(1`Q$`/P`Y&[7N1]W?#NX[+&,\#=KF7S=AZHV!O'4+
M*J%?R:Y3N<0I$1KQ63*O"&+%*^E(.5D-4?=_!^G7@\I-KVM49),S4JC!@3*A
MB@K2".UX):L*O=5Z2M2BRU,I$2/*(4X+4E>/%)&!#0%B?U`O=.GLT3FW*%[9
ME7E,]UF./+V'$#(F5%[]"Q:32/?J2$C7RK_%-FI&4LU5$X\NAP0?O!P0*Z;6
MLB2%2744"047")J1I)W/TN8:1U+O&)4%4I%)AFHI#S#&K6!F\I>_P8GFPC?]
MW1]Q&XV$QENH[<$IMJP\^J]LEI7*CN$R&Q183,.P2<0,.+FR'-%E--NS"F`#
M[YM/=X%J];=LTR0Y]*GX<S,%0&E*DJ+M[@`6+[>N6\I^HB!5:;\I*A))7I4`
M]V3U8?%NE[&._P!W+[X)/>JAN+M-<L2&%<LPU3H(050AZG\NAGSR[).$'HQ1
M2_,U3)P;;1174P:".OO#QNO.@2=%@T^)*NUQY;6O$ERB[-Y+CP;3T^KU4KLW
M44SB@J%!CZ4@.WE[G`8?1[6!/52Y?B$Y^'O!Y>/GX<N`34E[GXM9A!3G@RBH
M0H=1CE`.6HB8``-1T#41\.8\/<7NVMCBR"JF&NIR\M1'F'+3F.OT<@X;J220
M_$-@!)`&9;8#D$-0,40^G4-.$*TC,AD.!<<VX_B$/\5/V^\'+SY_1QBE)0H)
M60%$/'8S$Q$*!4D@@%Q[67UT1Y`H01#37W@Y=7AK]&O"A04`4Y'+BVP@I>3@
M!GP;;U"?UR_O#ANM!3K>-.]L<7NVMKZZ/^*0?/D8!Y?3^P>-FDD:MC(O\-VO
M!YPXLOK):Z>H7]X<^6O(?`>7#20$ZSZ2V?>T?>W-GK):`/J$T$=`'J#37C'A
MP.PY,NDDD;1FR@H00`0,40'P'7D/"[2G[PS;7S$;QBR"LD'5JH0.G3JU,`::
MAJ&OU<(%`KY8]8V;6V:2Y^QD!9(1$`4)J`:B'4&NG/G^SEQCP]VU[(0Y)6?0
M-K9ZZ.NGJD$?#0#`/,0U_P!G#5+0A6E1`4RI!4`4X@AXXAE,JD0`$ZA"@/@)
MC``#^\?/AXQ(`S+)MT_>;@6<$#H`A@,)QU]T2F'I#Q,`>8?LXYHZM4$KA'$*
M`PXES)K"(B4J]*@KP#V%KVVNY_6^XI8]SD!!8FGL7J;:[S%4B1<S=CBIY*V*
M2[^X,DI)BG',VAXQ-$:><QDU14$?7``-[H\%MR6M$MH2D:-$"A-0`MVY[BPA
M:MVP[D7-P0@I,M&*7['`D?!GE[CF6=U^'-KEHO&R7%S7,VX!A9*>S@:&X@'E
MG3>PLC-(MK(^-$1\Q!NE1CHHQU0.#@H$$-1`P<N.6WY:DSE0"*Q$$.1"22HE
MV(RQ;LNF=K$E2N;089C5%2T@)`U'2?47;@SN;1KKF:_[:L*WC<?3T<=YTL]$
MB9/*=+2C'$*C6K<N"GS"))%NWTDX8`@8H:)G<*F`!YF'B.J4&G0*K%%.)5+D
M^1684!Q:0H\Q/QZ5!BU,!$V$_B)<XI))`#MFQI'^LEIKZA-.7W@\1\`_;[..
M-,2&I^D@NS:45Y0]6`;;U4].KK+IJ`:@8!#4?`.7T\.20OT8LV(I,(:HGE'%
MM?61_P`0G+^T&O+QY>SA@BPR"H*#AGP9PQ.D>HA[*90A2F$3E`"AJ//Z?#V\
M^')4F)@@@LBR(8U1,$[RP7LU=U)?`>_)';+D2GUQAB`_Y/8/LE$?R!9^&D+E
M"(/6$A),%0"+"#9RC@B3E0H@9)N85?N"43B2M9,>W4U:&HF(H8.R4[<WDJ[_
M`-20LOK&CI]58`A45:PGYA>"7EQS>[[P]H8SJ+INNFFHBNBJ11--4ATU"J$.
MFJ4#IG(<HB4Q#E$!`0Y"'`22`5`YISX=K>L(<Q!BA)0I)U`$.+W@AX<T.-[^
M[VL;-\'S>4I1%G-V-TY_+V/ZDLY^'/:+>X34.V:+*)@99&+CTDS.'JQ0_!;I
MB`>^8@#*4.GHK,TB%#6!!40]0RQXM5W6'J?3^DMK*KU04CFJ+H25%Q6K^BD;
M2S'[>-[M\S+L,O6[69I=8B+94X?+4FA5HQU)K5QTICHC\S-)9RZ'Y@F$@9H`
M*Z<RZCT\2-5H9DK@314J."]))VXX=S!ME]9:M=?1:=ZG"73#FI81"F&[9#Q(
M/9MW-#+%?<2[G.;*1"Y)Q=L3HUSH\W\6:+GXNZG:MGPQ[Q9@_2*G(S[1V"B+
MQLHGJ*(!J74-?.;G[7MJ0FE2TU-#G`#:-H!PP][5+;'7CK_>](A7!;=J0YBC
M*>41.:4\T))2?*_#$$>.UGOQ9W8VK+(\1AK>1@VW[2[[.+)-HB6LIG#V@2CI
M58$$BFF'31DO&-72X]*;G1RS*(AUK$`0UC9BV("80CT>*)AX/E2XJPVN#'%I
M_J7GTW$FU>JE%BV_68B04\Q_*4#D4K5GAGC@<&GOE7(N1JI?,81].&BNZE=2
MV8TZ:99S;Z<(6KUQ[:EE(=Q&23>-$K^.;`DCZI#E*J?KU.70G`_+I2LF#$!"
MPH@D[#],VNFX:Q6J;.2DS0U08M$BPUQ"_%1)2]Z2,'*<Y/%HTT_>3F>PP\FO
M)X2:55_&;:<AY;(]FY-X6OV6^52/@I>*BZH\11.L\QV^A[&S47E%"E<$<K';
ME3ZVZ@\2$:1ED:?Q4$J4,`<@\9L*4N_:Y.2401:;,PEPI*.MRD$:EIUJ2$[]
M3@[>Q.C_`&1_9Q`';V-=P]0[6J4[<A'_`.TSNS_Y*RW^G&&.+7J'^EDO_CG^
M)J1IG^K\S_AG^$M;1Y]6G/0>7/73F&G%2I+D)/`>]KH`U1%`GZ.;\[WM26KN
M*6G)F\3;#V\'%,Q[8<E9;?7O+VX2ZH`Z:8KJ%:LEQ@(QC%I.8V79DE[*^E51
M1$C-T\4!N()%2*11<OH"Y8-"A4ZF5*MDJ@IEAY$XJ47#[N;G=S>8[67<L:H5
M&G6Z=$<S!U+."4I#W^;))>1QW;FGEFG</WH.R_D+%>3=UV=XK>9M>OUL3KUH
M7.4':+=UT&D).%9R$M78.U4BV!"I.G42<#N(UX+<Z9RCT](0TK)63>LNN';T
M%<M48:"H)4,].;@<\F)I^HWU9<S!77HHF9"*L#4#J`>=X'U-8![BO<TQ[L:V
M91VY]BP;7R7R<RK;3`M-<.3LTKG8KC!$LL*\E%VQQ<HUF$A!,^D3MP,H*9"H
MIB"BI#<`5O6O'KU;52XJBA$,JUD?="'D]CW.#VLFZ+P30:%#J<`!4Q%2G0D_
M>*G##>X%Y`8.M"VY_J+MT5"B]S,EOBJ6V^?M\6%NH^W<L.2%8-H5^@21@HRQ
M1\=4YB*KZL@Q.F"24DK)ND0.'Q1BG$Y0*8U4Z<T^83(1I6-$3"+HD0![]A.X
ML"2=&ZHU.!$J!F1!1&2]"-3B`<G#9W[&FUV@.YSF_<7D#,NQ_>[58NF;S=N[
MARI-N8]DWAV>1:S'/FT5,R!HAFJ,>TL4*[>-EE5&7^2D&#U%T@0A>L.(B\[:
MEZ?(P:]05HBT.96`?,"4OS&'WG9#-X<Q)8MTST],Q:#5H:TU.7!>I22-13VC
MQVL'*4[SW<+I&]K?3MBQHG-;C<FV3-MCPUL_QLYJ]=6KN,G$1?)Y"5GWK>(C
MXF3L00]5:HD0)(.A:$Z#KNE2I)G`YDJQ+8-`DJ[,Q2B%H!B$X/P>4O.1)PWG
M)@-=]W4:[.4:4AA<3F%*'!^DZG`N'[&,YL^Q]WK\6[9]X5KW*Y%Q[EG='<(&
M$L.UFD3DQ#3U:JUEBXB>--U2<:5J,IE:BBS+YRT3;D0?KM/5(4RBI2%,!@:O
MS-G3%4EH5)AQ(<J/47$=[\?%CV@2M]P*;,Q:JM$2:/I#P?!H<J;.?U+V06!\
MAV#?KB;&5L5*,FQQ/7U(]O$M%ND54X5RZK^,WU8("9O<'U%7R?\`654#4>"$
M5CIFAT!$I&4AWJTD^+_BP\*#U1(YWSB$KW:P/!I(]G;N5;E\X9NSML*WYUZ*
MAMUVWU!S)ELD7'Q\/^<X"'E643/LYB.B#?(59:.&69/&C^.*DUD8YT"H$(8@
MB>(O*UZ#(2,I<5KQEF4F%:5H4""#GWASVF[%NFH3=2F;;K@*I^7!(5Q&8[C[
M6$]B'NE]VS,&ZO=QLRVXR+7+>5I[,]PK^*;C>(>JMJ?MIQ70KI:8NRV)X1I"
M-&CPRC5Q&-D7$L+P"&0`J:#APL0HEL[:=K2E.E*Y.K*)?DH4M`^^HI23IWXO
MR8'E+QO.H5N:H,D-<8QUI0K/0D*+M[G`#'8T@\U8U_43[!:C*[IU=WM3W<U"
MEMC6C*N+"PYIMK&5MF4CF9<I5B5J=?=NX2.;D.9TO!N6CMJ@0RQ4Q(4XAPR<
MSTYK,2)(IEXD")$41"4<';L7X/.PAI6?DNIM!":E$F$QY>&-41(4]^_!WN8Y
M>S3N:X;W4;&7F]AX=+'M9Q_7K6\SC`/G99(^/;%0HWYM:XQ%V;T#2C%VP,DZ
MBU.DIW+=TB40!03%`)K-JS5%K":,C4N(M0*"XO6E>(=O<]V#Q@U@42])*M6^
MJM14"&J&DZQ@Y)22,=SW/#][`UQ5G3O,]YZ9O.7=L.8H/85L^K]FDJWCZ2"/
M,XM5Q=1:A2*>O)LH:3L5@E6J)DAD5$56$2T74%ND58Z9S`7524LZS9:'*UA*
MIBL*`4L#%P5B`[80&KN!/7U?494Q0HOR=.2HA*E'2%:<W'[V>S)G/V_[^.X/
MV^=[6,MCW=)M-:S'C?/CIG$86W.0[-HP4)+R<DG#0QGDFWC83YK#'GG:,?)-
MI%JG)1JSE!<%5D#CKHJ-LT6Z[>CUBU#RHLM""E0R1J>,20'O[\BX[FE:=<U?
MMZORU$N;\2%&(3S,TEY(!U99C'<TD<H[Q-RD#^H&P7L]B\HR#/;C:L+EL]AQ
MB6(KJL=)3HT._P`N9\I*JQ*D^D?YE#-E>E-T4@"D``&@F`8^4H\E$Z?FL1D?
M]13$"2HC,X-(3-:J<#J,BD0XA_+50PI*7X.+G^+'?RM)OH3&&19V+<'9RL'0
M+G+Q;PI2'%I(QM=D7C)R4BI3I'.W<H%.`&`2B)=!`0UX")1QC0PH8*B`=Q./
MN:Q9^+R418@P*8"E/X@/:L;VQ-P?<N[A':WW!S=*W(QR>[MCGR*J^-LKW>'K
M$5&5VK,(N@V">BG#6%IC^-4(\C7K](ACQZRGJ+A[P:`(65<5,MVU[FEA4$&)
M2A#2M24XZBK`#`XM45JU2Y;HM.<B2D1U3,<H0HEVD`$EQ.3\GL&KM'X/[K62
M+1O';;%-R6/L.3=9R9!L-P#NV)L3(W>WJR-]3BI.'^(Q_;!*W;.V4J<P$(S+
MTN2ZD'4`*>WI/67()E_S>#&C<Z"%P<#Y$.#AGALPQ8`LZ0O:>,T*'%APEPEZ
M(OF`U*?B>.6>365NX+EW>YLJ[,;C(%HS.S'>;04<8P]XS#5(V&D6$K-SN2V,
M9+/(MG+UII$J-GE??)MQ$8Y'I$!$I2F`!XJNU*91*[=WRZ4J,BM"]*2\;`Y_
M%[VN"\9^OT2R8<TJ(E-3AJ1J4""=NK'CAVMSW3NK_P`H?:%VQ;N<VKCE?.V8
ML2T%"IP#D[2$<9)RQ8JZ,J\DI4L2V;H1U>B4$5'LD=J@71("I)E!19/C!:2:
MO=,U19?R24LIZE!_E2,QWMI_G9="LR4K4TGF3\TEP!S*B3CW?4T!J!@/]1MO
M%I<;N,F-YM-VI%M[,+50L'I1BU<*E!2+;XN#;SD3`T^?&$(\;J)F*G+N7[TI
M#@9<"&U(6;GJETWI2X4BB7BQEH+EK&+]C^..YAZ2IO4VM)74OF!`@1!J0@JT
MX'(.=@\9/8D/:NW"=S>PS^=\#]QG"9(M[@1O''C]R,<A%PT5D)5XB9ZC$LX^
M'31A+L8\&F+TLO$(MFZ10^'=))N1`.!Z[:;;)1!G;>BD&(YZ'X@X9[1Q![F*
M[*J]U*CQI&XX!*(+W+*2'YX`N<K@[8PJ\.;@N[GWE\A9\R+M*W3479EMRQ!?
MG%*IM>38%>6>8$2+.H9>Q+,8"9L+]Y(QA$W#MPNJU8IJ+BBW;J"D8>"B?DK8
MLJ5E$5F6^87,P=95D`2-A>X.V#/VL'R53O2]ZA.FC1X<LF7B%`2]RG8[,3WN
M<Q9NW*U[R5%R_D'%7<$E<1Y3PG7:<WE*)G:L$CT;1:+&ZDA;LX%LG7VD$99!
MK')JKOPEHE!PB(H@DLOUB8`ZXHUH195,S1A$2LD`C'+LQ+&-JIO:6G#(7"$Q
M8`R4<=VW:7-%K-VVVI[K^ZYNFPQ;>A%.<VL1<A7)D"]:];N;%A05*_/HIA[Z
MJ;-RL8BR?+U&RBB8_:XGI6?F*3;\I/ERI$++T?NO+\,<<&\67/T\HW4C]3%Q
MVI/K69A=&5,2RW$B%&")5W]4@][GM+/MI[I[-"P^0]GFYR10KV;-K+9^U5E+
M`Z,B2TXN@0+\/.E?/%$@>EK4>*6J_BM&*MUN8B?B+N6D)F5PZY24_P"5F"`I
M*0]S]X&3VMWH-U0G9*4G^F?5%7)N.A(4OG+.D18*'N(4IVHA(&3\.QHDIQ4K
MW/,T9OW2VIH^)M0VSTK(T!@6N22;A".O-U85V1=K6=9$^B*B97:)7KDX@;00
M9MQ_NU"\2D"+)VW)2U.@)2J>C+2=0^Z\A^63G]S5=-4Z?_47<E<N^I&(GIQ2
M9.,F6AJ!"8D6&E3E)U!RCY7EW#)G0V&:E[)V8@.;41J.Y[F.@"812F1'EY#K
MY>7AQS5GF)O6"(Q?%\KSOXL0=&XB3^D>JQ%>5*DU`A^&&0S:8?9R#7M^X6]K
MJ]`.GB'_`*UG_'Z-0XB;SQK47^S_``AK;_2@E/\`\'TMQ#S#B/\`^-$:0>];
M:[1MU>"KYCVU1+1S-)P,G*4*>5024D*M<(^.4<P[Z.7%+UD4'+M`B+M$#@1P
MW4,4P>`AQ4BJ1J=4H&D_AK4XC?BX^#&?5[I[0[]LJ=I]6@I1.09.(N6F$#\5
M"PDGU#$!X<[)W%HL=G;,D[F;9[!1=Z<#*VS#5LG\5+2#H0>/5(>*;,G<""KE
M4IU3JMHF1!EZ@CJ=-N77D.G$A=DDB6JRC*J<B(@+.YY>]J\_2K=%0NCI7`D*
MQICS5,FHLGK47J*(.DI))QR4[%BKC%1QB%#X1N*238[,I!:-S`1HH4`59D**
M/25HH4I>I/3H'I#ER#@:&H>4EZF],&#+`A2H2-?I#G.<?!V]NX4'0H_LXT[^
MQMZ?4!Q:I5MR_P#U,[L_^2LM_IQACBUZ@/\`ZLE_\<_Q-2%,_P!7YG_#/\):
MVE]\/VA_NXJ0>A/8/>UTC^^/?[FJ4?I>$4OG_<N<>F3UC9YK*'J]!/4]()+)
MYP3%30#BF4W,"ZZ`//34>+6ZA/$I3#_RH]P:F^E@U3573_S'Q+2X_4[MFZO:
MTLZZZ)%3L\X8A6;',4!.W64>S+515$_,4SG;.#D$0Y])Q#P'B.Z:"*JY$<G^
M\,&(>YS3G5J&?Y304YB/"]Y82'?8B[<GL<[*MM:R"<938;&U+C)&9?-CO(2`
MN,EB3$#^N3<RW!)R0[9E%Q$@J9,4SBHBDJ4"FYAP6V'RE5VM0XD)<:.=?D07
M*4Y9)<>QY[&`NHT&9B6Y0QKY:2`-6XN2[X,1*)V@_J(YV(BIN#[IFWN2A)F.
M8RT/)1]#9K,'\3)-DGD<\9+)8D]-1HY:+$.F<HB4Q!`0'B%CW!TY@#EBDS(F
MDQ"%J6H:<W%[SD#L:?@6]U%4E,2%45F`80T.6\988.S=^QONV,=J3?5BCN7M
M-\^ZG<_@G,MM3I,_6,F)41G*0URF$+!3TJS4%'\*UJU?@T44THM$XJJD347(
MVZP%0Q1'C3<-XTB<ME-OTR3$*73$Y@)`#B-H;NMJRJ[3KH_-JI.<R*48C4\G
M>",\6C)V;<>UFQ]\7NL7Z78(/;#C:RY3;5%==,AS1*UWS(]83K]J8P"9%VM&
M1`-NLH@/HK*E'4#<2E\1HDM9=*I*2Z''A)B'CY0[Q<T/8,@B)?=4BQ\8B%J/
MM5]K%B[Z>_;(FP3:%&7'#:3%',&5K\RQ;1+#)LD))E3#NX>6G9JU%CG8&8/I
M5A&Q!DF*;@ID".ERJJ`8B8E,%V-1$UZK?*3?H`>0-NX/][&?42O3EMT@3,D7
M+4IPX9?7@P_L4=E3??EZC5_*6X+N\;I:SEZY0T=:GL%C:P6-]5*RM-LDI1"*
M*\-=(-N]49%=`10S!HS;@<#`D`E`#&F9V]J+*S1DI*E01#>1LQ=AN8>DK`N"
M;E/G)VK13$*0<R<P_-[1)[6F+KWA/]0KG#%&3,[R&Y>]4?`=[A;#F:8340F[
M.X)%XC<-F,Z@K(2BI)>LLETX]<#N%C`HW$=0UT"=NVI0)^Q)(P)<04<Y^&6W
M`<&@++E9RG]2IF4F5ZW05!^]PP/:<R]G:[`EPQY&=RGNL4N57CVF4K7DBS2=
M/%VJD61EZE6<P7T+='Q)5`(=463V5CW#A-,3&%/I.8.E,!#BZA09TVI3%N.A
M,%'=Y$N^+=O3><DI:]*K*3#A-1(T71O(YA+O9CW-:[R]9ZA3L2Y*MN0WT9'4
M6NT*W2]R?2RB98MO7&,$_7F1>BKH0[<S$IRB7Q/KT@`B(`-72J8L6;A(EL8G
M-3ECC@UR3Y3`DHQF\$B"I_8XC;[&HB;`J3D.=[$G>&EJ4QE$:E8KU`2-0:)`
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M$9`$5,EJL1+T`4$H=/4'#3KUMFF2TW"D9;EQ)J!R\`';<<SO:0G;&O6J5*4-
M6FX<Q#1$>\*R#P7.*1VY=[>YSS*L:]^J.VI+SSY!@64P3#P<>Z=*`BA(2TKC
MK*S)@V0,H"8&5D)$@H)`&@F6$"@`F'3C5!4N)TQCPP#I1.^P.>7MNG"9?JK+
M2JR]2(*4]IP'O:S5N0LD+4MOV<;'8I)G#P,'B')4G+RCY8$6C!DUJ$RHLX75
M-R(F333Z1$0``$1XK:0AF8GX$!&*U14#Q#6Y6YB'!IDT8GI$LO'^R1\0&KN_
MI1`$NQ3,Y#!H8NY*6#3V#CJC"'CI_6X/^KD$0*U"AC(0$>\-671V)#7;\<(S
M$PI_L+>"_3%?^XO=/'R'<!3N?E_YWFC3]X!Q)=5".52L?^YI]P;FZ2_]KJG_
M`(@_Q%B`_J.>?:;SSIIJ%JP[_J?6=.!WIN_^:H+OZ*O@Q'U5(_DZ,_\`VB/>
M6KP=PXBM>V<_IY\D7ILN^P/5J;427A`R(KQJ3Q%;%$](_'%,DN@(NJ=#OM$S
M%$RR:"A0`P`<`L:W4HC5JY($N/\`/JAG1V;?BU97'K1;=N1I@_Y$'S=K\/AF
MU]"OS$+8("&L%>D6,K7IR*8S$#*QJZ3B-DH62:I/8M_'KHF.DNR=,%2*)&((
ME,F("'(>//BH:X,5:9G"*(AP.8;T9+*AQ(,-<MC!Y8<[)VQN(LW"R;Z:@6<K
M$OI:$39$G8A"09.Y.')+M5'4>$O%I+J+QY9)F0RB/Q!"^LD`B4!+KPL1\.&8
MBGA(#WNW;M[;@8:R894...35?\R]A'-.*<OW#<9VJ]Z$_MNG+O(REBD<73,E
M+-:2NZ?O%Y-Q$Q-KK?S%!W6PD%U/AF$O%2*;4INDJW24-+0IE_R/)A4VZI&'
M.4]$-P4H8I#L%8Y$#$-4-0Z=5&!%BU:RYQ2)R)$>H/<"\Y`CC]3.7VR>Y-O9
M1WI6OMD]R"H5Q3/4149*WTK*521BFB=ECH6(0GE$IU"`*C7IEC-UHYWK"49H
M,S^HBH@X0]3F3ENFVJ4FCBZ*#_Y1$+@-HV=N!P;=:-RUO\^5:]?+ZFC,]F/8
M</@TBL;<N^UG'R#^62,_\+CSCAFO_8LI_6^MJ$M,'_\`9%<_]*5_#*M[CN3]
MMZ3W56*@Y.Q#,-J7E))ZSH&1YDSQ6+3L.(YU4S.:=/3M#)GDI.LL5U!3;FU!
M\U.=N;4`(`<E"KT2FP#`CE\,_1S%G7K]/\QU/J,E<-LS'R$Z5A$VH$C7!R)P
MS(#^T%IO'P[2L";1;?B?';$L;4:;A6[1L<B.@N7:A*G*K2,K(*_:<RDL_,HX
M<*&]XZJ@C[.(M$U\[4X4PH.5SQAN\V`:V$6G2K+Z71K5H@_RDM3(VI6U:A".
MI9XJ+R>+"V[>\++S_9ER=7H*,>S4],P&X^)AX>,;G=R$E)R'S9NR9,6J)3*N
M'#A<X%(4H"8QAT`-1X)*['A?SI!F8WH3I]C>;NA4M-5']*-2E9*'\Q-1?GPA
M!QS/E3W--WM24BX8XV.XDJ=]JT]3+3'JW(\C7;/'.(F;8$<VZ9<,Q=L'12+H
MF<M5R*$Z@#J(;4.(2ZYN%/5>)'@.Y:BESN"0#XAKJ_3E0:K;G2&FR%9@F#5$
MPEZT.<4ZHBRG#B@I/:ST[S=S%,VKX'OV3+=(M6SQ&"D8JE0RJZ97UHM\@P62
MAXN-:F'U%Q!TH"BY@`2(MTSJ'$I2\<M(ID2H52`[^[0IY.[Z`,1]7[WIG3RQ
MYVLS<0&<B2<1$.$_$J((#AF<WEP^#1+[,^$K'B79Q%3UP9+Q=DS#<IS*2[)P
MBH@Z1A99)DPKI7+=4"J-S/8V-!T4H@!BI.":AQ(77.0H]3(A>E"0GO'[6K;]
M)UM5.@=+DU*JP^5-5.8BS83^Y%TZ">)TD^QBTE_NC?\`1$?WEUX%4J*GD["W
MI@!TO_9+8MRZ?/RT]@\9$2(B>7M./L98IT:8@S!=[6!_BKMKY=H7>4S?W&)*
M\8\?8DR=C]]48>FL3V`+ZQDG-7Q_`$7D2K19((&A'-3<&$4W)S]!R<M1'0QF
M[H$6T$V_MA*!\6`I6TYN%?\`%N*./P50W)[P[[6-NHJ"90.!>H?(H#S'I\-.
M0@(Z\!O*\Z$[,/#%CL%:TKCHS!(8)O9O[:>8NWA([M'65[OCRYI;@<EQ-XJO
MY#4GCFAHV/<VY91G._.XN.*#PQ+$EIZ`J$U(?GX:F-W7(FX8<J@#&5A"'[!]
MC!%F6Q,V[,S<2/BF97K'M^UGV[PFR/)'<&V93FW/%5IIM.MLED&AVQ&:O9Y8
MD`FQJ[QXN];J#",))]\4X(N'I:)"4?,0XTVG7(5OU3\PC>@P8B.]8<&D+UH<
M:X:(JFP/[SF(7W(+RWL\C;`,:[C-@F/]E.XE!&:C:UA[&%,<V6K*&(_KM_QW
M4HN!87ND/7R`*-W4?),5%$`72Z5VJQT5TQ(HH4>&6KLY2*R:Q(C4HQ"7<%/!
M'L)98UL2U:M>#19M6D!`#QL*<7CO'L8(]*[;??OVEP:>"]IN_C$=HV_1YEH^
MGN<C-$D;+28,RQOAV<;'V:@WMQ$%;)'$2MF,BHS3-J*1"`(`!U&N7I_5.7,3
M\BM4X_\`%2#@K?D=O$,"P[5O^CZI2WYQ/R.PJ(\K^U_@&)1VP^UG>MFUTRGN
M/W&;E[MN2W49R:,X[(=C5F;"E06<:S=)/TFC")E'15[)*(*IE31D7B*)6;4!
M0:-VZ9U.L2N:O2E>ABGR<`2U+AX)3D6++1M2/;\>+4ZE&,U58X\ZLW/]_@W1
M=OCMLY?VD;\M^.Z:\WC'MDH^ZN=EI2C056/8!LM?;O\`(DO;TT[.64C&<<54
MC%^5,?AE5@]0!T'3GQ(W#<TM7:-(2,/!4C#"#W)`^#<UIVK-T*O3\[$Q3.*4
MH<'J*OBTP^Y)L`Q]W&]MDM@6\3CRGR;.:8W3'=[CF:<@[IUYB$';5A(JQRRJ
M*<G$/&$@Y:/6WJ)&5;KCT*$.4I@@+<KDW;U4^=E._B&G[KMN5NFF?)36!!>#
MN+!<Q_L2_4,X[JD7MWK>_P!P)&X:@8YO6J_E)U$+V#)<#3VB?P+5E$*2>/SV
M8KAG'%*1MZT@=5#I*0CDI2@;@RFJ_P!/IR/\_%IO_5CBY^#^Q_P:OY2UNI,C
M+_ED*I`4S+4_$#V/=]3.EV[^R?EC8OW"Y_=%)9WALO8YF\5V*J/9:S*S9LR6
MK(%V+4)*TV^Q)*L5(1)B_L\2].0A7[IP5NHCUG4/UFXYKEOR%<%&@6^B6Y?R
MR]0=L&+O!NNV.GU0M^X%U2-,A:=!?QU#'Q+!,V1]O.Q;XMV/<MN.(<]6O;AN
M3VZ[F9.S84R?7UWORMJ^LV0,HH3<38VL8JA*`RD$HI`H+MCB9(`,51%=(YTA
M-Z_<GY)1Z;*S$(3-+CR</7#W/0G`=F3`]`MJ:N6N52:EX_R]2@S<31$WD1%!
M_?G[&)+>>U)WO-XB#'#6]3N`X]:[<T)!F%D;XY2.XF+M',ED%2_&P$'1Z"WG
MG@F2]1()IZH@FJ`*'(H8H%X'(5TV31]4:VZ;\O458A1V$YD/)8JBV9?E34F7
MK\_SI!!Q3O`R>`!CL>6L;[;-HN$]L&W*K[7L7UALEBB`KLG7I",G$T95U<3V
M`BQ;=,7%0Z2:4S*VY9TN=\)B%3,"OID*5(I"%K>L5:=JU4_,9A>N="@2>```
M'<`&LJCT:5I=+_*X2=,J4D`'CF>\M7\GNS!O]V2Y8O5Y[1.[V`QWB[(<G\XF
M<`9@.NM`PCI4RA4FK->0KESKDZPC$U!29N5F;241;]*)UE@(!QL)%X6[5Y!$
MK>$ESEPPX1!M`R!RR[>QJYC6'<5%FXD:S)WE&(7F&2'A^)..'9@SH;=>T?OC
MR;N9QANO[GV]*2R?9\*3+6QXMQ-AR8EH&LPTVD<5"GD).+BJ7%Q<0KZ90>-8
MR/!>31U2<N11$R1HZJW;;T&FFDT*FB&A1>(CGD#)VW$.&9<'MNHUDW3,U1%7
MN2I:H\`OY8+\!CL<`"7Y#8TC^[KVB1[@KS&>:,-Y-1PENJPR@5M3;XLG((P\
M]"MY09V*B)F0@S!/0,I79H5'47*-06.V,LJF=(Y5`$G):%V1*`J-(S?XDC,!
MZH?!SGN.8W[6G+RLTW"45JCQ.56H:'(_?#WO[<Q^QH$&[5_>4W7P"6(.X!O^
MKBNWB.:K_,J7B]P1:SY1<QJ!U*]'6^;C*)3RNXM671;JNEI%204!,IC`@HKT
MF+,PKLL:B0Q.TJE/JZHGK>2`7\/L[6%OY1ZA5F5,A7Z@(4II+P]^OZ<=^63$
ML[+G;URSVX=NV0<09@N5!O%CM>77^164ICXTV:&2C'E:KT(FT<?F"-BW8.TG
M$0J;W2"3H,7GKJ'`S>M=3<E0$Y".F;*!Y3P+W`;BQ=T_MV+;%,7*1%`2NL^;
M^EF&&C<NS+W'MM&Z'.&7NV%NYH6*L>;A;(_L-IJEW%VVDJZO+R[^=4CW;%S4
MKC7[&SK\G,.QBWB1&SU)LH*1B^)CE:;ZMNMTR!+W'2^9/RT$0PO$/=D=FYA*
M+T^N:BU.--6S/\F4F(NLO(>XE^G$./<Q+-W6P+<GN;[4L?LNLV;JK=-R#N,Q
MG^=<U74)I*O6NR56Y1]HGY9Q\!&N)<"/$VID6W^6+J)2=12`.@#%$N.FT.Y/
MS=$'7)I"@F%N>YQ[BQ;<-N3]>M44>,K74"I!4O>4DE_BYG`3[9V/LK=M/$&P
M?<X=A91Q_B>D5%>XTE1=!S7<@TR,^#C;U0W\JT3<MUV3@Y^@JZ`%<ME5$5B"
MFH8..==S3LM=46XI&-RA,'T;QM'L;?!M"3G+3@VW.IU&72[B]Y(^G[6#Q3^V
M!WWMI<1_!':+O_QM.;>VCA9K4AO_`/E+!2X54ZY4V\7%6:AWX]>,@5?K!"*D
M@:E4#5(J8<@-%7-T_J&B9N*FF-41CJ!V[\"'[][!D.TNH%-2N3MZ?$&0R"7Y
M#!^8)^F#$1[=W:`G]J@9WRYGK<_DS-FZG<S5):HY+R?`V>>B(ZOQTNB<AWE4
M&76<NY>W1RHD.RFI%#K8E3*FT;-TQ.4XQ<=W0:F8:9.6$*0ER]$/:IVSOW;6
M(K9LJ+28,Q$GI@QJI,H4E<1[]&H$:L=H^G"$%=[3W>&V5N)2L;`.XE7K'A-U
M(O7D30=P#)1Y(0/QRZCAQJA,UB_5[XHZI]57#`T>#E34YD2B(@,\;LLJJ"$B
MOTO\5,+'3M<.!!/P:%BV=?E,F51:!4P9=1VGW@@CV9-,/MN]IW,>!]QV0]]N
M]W<`QW$[NKY7G559/()DY3JE%A7Z3-M(&:/'K6*.^E%8Q@E'H)-F+)@P9@<B
M1#BH8P0EQ77+5*FIHU)E_DZ.C(;\?H6G+5LJ8I=25<%=F/FJPL8D;'M,2M;2
M;W"=QO(>[]Y8*JOCZXX@:T!A7$#R7YM:RK=&JD.]=E.R)%BPZH%00$BPG]XO
M+B+CU@"WTTP9@O'<_P"LL!T?I=6Y#KY4.J*IA/Y),TTRKMKSI./`%+$H+ITE
MT'4.D-!^D-/'B`&0[&]``.``9O<EUQY<,?WNHQZR#5_::E9:\Q<N^KX5L[FH
M=['(K+BD4ZOH$4<@)^D!-TZZ`(\=$M'3*S\*95DD@^S%H&YZ9'JUO3M,@1@(
MDW`7"'`J24L"7!FPSNJ;<J!&XRQ#NNP;5:.P=R,DA#A6OFYDY*9<"\DW(2$W
M09%^8%W)A'H%02%^Z`<&DU6;9J<4QYF`530/F..)VG,-XYM?HS^HRP:$NV;*
MN"F0J8J*J((:X(,2&"7N*M)>79G:SQ'V_P#>A63$BN]?""2:@]!W"=#C3&1*
M;W143!+&A5.L@#RT$!U#Q#AGS=G(_$ARRN<['/'OU,01+._59,)2E5VTZ%+J
MP48,NDK3L)=I>_;@6[?&7:D>6K(<+F/?#N`LFZRVUY4KB#J4B@ZC<<13A)4J
MY`5C7+HZLBS17*!OATDF+942AZR:H>[QPSEU1I:&J6H,(P=6!&&1VX-)V[^F
MTS==AW7U2KDW<,:5(4B%%28<)"AMTG8_<'%C+1J:*+8J#=--%!N/H(I(IE21
M322(0B9$4R`!"I$(``4"@```:``:<#,0.5J/K4'GM.;^+>K)="8<%*(?*$`!
MR!#]*4#TCM&UOOXUMN9!T\]/KXS;Q9"[:VOX?+[&GE]GV>'#?+CEQ^UG>9^+
MWM@^GH&O1IY:].GU<.Q9$Y>7+@RAT_=Z?JT\/JX3RXY,I?M;!Z/O=.O+QT^K
MQXQ3G>;T\63;Q<V!T:<NGI]FFG_#A<=C('.P<YD]SE]CV>']'#1IU'2[5XLH
M>[#TMM[NGEI]6G"J=][Q9`[8VH^GY]'U]/&#3CI=Q^UG![\'O;?A61M?<_L_
MT?7PF&O9K\6S%W[K?.OTZ$Z>@#=9.G4`$NO5[G4`"`_:\/KX</47>IV.]M45
MV&_Z9\&"-VKO_CL_F+WZ?R7?Q8_BI_$LG\S?\0_G/R'\X?FZ]^E^3?F?^6^`
M^??-/[CEZ7I^73P57`;@^0DOS00_D^2GDZ2=6C2'/P&.G//%@.T/Y=_,Y_\`
M*#%^=^87S=0&G5K\VEQRU9<&.`'3TA]G3R\-/;IP*>UK!\VW-M@Z=`TTT\M-
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MIVGS^GCDR#3]US:CZ.H:^GKY:].NFOEK[>,+MK9AR_\`=>'U-R<*RMJ/3RUZ
M?'EKIX^SV\(7;<V;Y.&?C];:_A?]W_U?JX5.W3GM<SAZB[U[=[+^'H/V-->?
MV=-?+7VZ\8R(TO\`PW/X?8V?AZ?<TY_U=/;Q@?JP]7BRJR.OTNQ?\64O1I[G
<3T_V=-/Z.7"E[\<V9#Y>G\+3HX.=X-MPC/;_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
